Viewing Study NCT02511132

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2025-12-24 @ 9:54 PM

Ignite Modification Date: 2026-01-02 @ 6:36 PM

Study NCT ID: NCT02511132

Status: COMPLETED

Last Update Posted: 2022-12-22

First Post: 2015-07-28

Is NOT Gene Therapy: True

Has Adverse Events: True

Brief Title: A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma

Sponsor: Gradalis, Inc.

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module Adverse Events Module Baseline Characteristics Module Participant Flow Module